Group 1 - The core viewpoint of the news is that Guichuang Tongqiao (02190) has reported significant growth in its interim results, with a notable increase in revenue and profit, driven by its vascular intervention product lines [1][2] - For the six months ending June 30, 2025, the company reported revenue of 482 million RMB, a year-on-year increase of 31.69%, and a gross profit of 343 million RMB, also up by 31.5% [1] - The net profit attributable to shareholders reached 121 million RMB, marking a substantial increase of 76% year-on-year, with basic earnings per share at 0.38 RMB [1] Group 2 - The company’s revenue composition shows that 63.3% comes from neurovascular intervention products, while 36.7% is from peripheral vascular intervention products, indicating a strong performance in both segments [1] - Guichuang Tongqiao has been actively expanding its international presence, particularly in Europe, with successful penetration into markets such as France, Germany, and Italy, as well as emerging markets like Brazil, India, and South Africa [2] - The international business achieved revenue of 15.72 million RMB in the first half of the year, reflecting a year-on-year growth of 36.9%, and is expected to see further acceleration in growth in the second half of the year [2]

Group 1 - The company, Guichuang Tongqiao (02190), announced a share buyback plan [1] - The company will spend HKD 1.1967 million to repurchase 50,000 shares [1]

Group 1 - The company, Guichuang Tongqiao (02190.HK), announced a share buyback on September 1, 2023, spending HKD 1.197 million to repurchase 50,000 shares [1]

Group 1 - The company, Zhichuang Tongqiao (02190), announced a share buyback plan [1] - The company will spend HKD 1.1967 million to repurchase 50,000 shares [1] - The buyback is scheduled to take place on September 1, 2025 [1]

呈交日期： 2025年9月1日 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 重新提交 FF305 第 2 頁 共 7 頁 v 1.3.0 FF305 確認 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年8月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | ...

Core Viewpoint - Multiple companies conducted share buybacks on August 29, 2025, with Tencent Holdings leading in both the number of shares repurchased and the total amount spent [1][2]. Group 1: Company Buyback Details - Tencent Holdings (00700) repurchased 919,000 shares for a total of 550 million [2]. - Weichai Power (02338) repurchased 16.42 million shares for 250 million [2]. - China Hongqiao (01378) repurchased 8.92 million shares for 227 million [2]. - Hang Seng Bank (00011) repurchased 210,000 shares for 23.52 million [2]. - MGM China (02282) repurchased 1 million shares for 16.06 million [2]. - Other notable buybacks include Zhongxu Future (09890) with 664,200 shares for 10 million and Weigao Group (01066) with 1.26 million shares for 7.45 million [2]. Group 2: Cumulative Buyback Data - Tencent Holdings has a cumulative buyback of 46.66 million shares, representing 0.508% of its total share capital [2]. - Weichai Power's cumulative buyback stands at 39.14 million shares, accounting for 0.449% of its total share capital [2]. - China Hongqiao's cumulative buyback is 88.67 million shares, which is 0.950% of its total share capital [2]. - Other companies like YUM China (09987) and IGG (00799) have cumulative buybacks of 545.32 million shares (1.460%) and 13.60 million shares (1.166%), respectively [2].

Group 1 - The company, Gree Chuang Tong Qiao (02190.HK), announced a share buyback on August 29, 2025, costing HKD 1.1474 million to repurchase 50,000 shares [1] - The buyback price ranged from HKD 23.28 to HKD 22.36 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 歸創通橋醫療科技股份有限公司 呈交日期： 2025年8月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02190 | 說明 | H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | ...

Group 1 - The company, Guichuang Tongqiao (02190.HK), announced a share buyback on August 28, 2023, spending HKD 1.116 million to repurchase 50,000 shares [1]